Psychiatry & Neurology Doctors in Weston, WV Accepting Medicare

5 Psychiatry & Neurology doctors found. Showing 1 - 5

Scott Gilchrist, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 135 Staunton Dr, Weston, WV 26452 Phone: 304-460-5123

Dr. Paramjit Chumber, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210    Fax: 304-269-0494

Dr. Deep Yadava, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210

Abid Rizvi, MD Psychiatry & Neurology - Psychiatry Medicare: Medicare Enrolled Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210

Bahar Altaha, MD Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 936 Sharpe Hospital Rd, Weston, WV 26452 Phone: 304-269-1210

News Archive

Study examines adherence of U.S. adults to physical activity guidelines

The proportion of U.S. adults adhering to the "Physical Activity Guidelines for Americans" from the U.S. Department of Health and Human Services didn't significantly improve between 2007 and 2016 but time spent sitting increased.

Research may lead to elimination of surface-induced thrombus formation

A University of Missouri-Rolla researcher's investigation into how proteins adhere to surfaces may lead the elimination of surface-induced thrombus formation, a phenomenon known to cause blood clots in artificial arteries, valves and veins.

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.

Gene therapy can improve regenerative capacity of injured RGCs

Because the adult mammalian central nervous system has only limited intrinsic capacity to regenerate connections after injury, due to factors both intrinsic and extrinsic to the mature neuron, therapies are required to support the survival of injured neurons and to promote the long-distance regrowth of axons back to their original target structures.

Read more Medical News

› Verified 6 days ago